|
As Chairman and CEO, Candace Kendle has provided the overall vision and strategy to grow Kendle into a leading, global clinical research organization (CRO). Under her leadership, the company has advanced to become one of the largest providers of Phase I-IV clinical development solutions worldwide with more than 3,500 associates and operations across North America, Europe, Asia/Pacific, Latin America and Africa.
In a market growing at 13-15.6% annually, Dr. Kendle's focus has been on positioning the company to compete at the highest level for large global clinical development programs. In support of this effort, she led Kendle through a strategic transformation in 2006 with the acquisition of the Phase II-IV Clinical Services business of Charles River Laboratories, increasing the company's size by 50 percent and strengthening its position as one of the leading global players in the CRO industry. The successful integration, completed in 2007, has provided Kendle with much greater scale and competitiveness in conducting 'megatrials' - the fastest-growing segment of the market. Demonstrating the company's ability to deliver against customer needs, Kendle was named "Top CRO to Work With" in the Thomson CenterWatch 2007 Survey of U.S. Investigative Sites and "Best Contract Research Organization" in both 2006 and 2007 by an independent panel for Scrip World Pharmaceutical News.
Dr. Kendle is a recognized leader in the CRO industry. She is a founding member and Past Chair (2006) of the Association of Clinical Research Organizations (ACRO), which fosters continued advancement of medical product development and expedites the introduction of new medicines and new treatments to improve health and save lives.
Dr. Kendle is a member of the Harvard Business School Alumni Association Board and a member of the Committee of 200, an organization of preeminent women entrepreneurs and corporate leaders. She has received numerous civic, financial and pharmaceutical industry leadership awards.
Prior to founding the company, Dr. Kendle held senior faculty positions in the pharmaceutical programs of several leading institutions. More recently, she has played a key role in the development of the Master of Science program in global drug development at the University of Cincinnati. | 